New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

OBJECTIVES: To determine whether a chorioretinal venous anastomosis could be created in humans and to evaluate the influence this has on patients with nonischemic central retinal vein occlusions ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

It can happen if a clot creates a blockage in your retinal artery. Your doctor may call it “central retinal artery ... temporary vision loss. Retinal vein occlusion is when a vein in the retina ...

Objective To understand the efficacy of aspirin use for preventing ischaemic stroke after central retinal artery occlusion ... acute coronary syndrome, retinal vein occlusion, new-onset glaucoma, ...

The Ocular adverse effects of COVID-19 vaccines include facial nerve palsy, abducens nerve palsy, acute macular neuroretinopathy, central serous ... 19 and presened with retinal vascular occlusions, ...

In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion.

A team of scientists at the Indiana University School of Medicine has identified that an eye condition affecting the retina, ...